Amgen, Celltrion and 4 more win NHS Wales ustekinumab contract
- NHS Wales Shared Services Partnership
- Wales
- Open procedure, 6 bids
- 1 October 2026 to 30 June 2028
NHS Wales Shared Services Partnership is buying the biological drug ustekinumab for NHS sites in Wales from six suppliers. The six are Amgen Ltd, Celltrion Healthcare, Fresenius Kabi, Gedeon Richter, Sandoz Ltd and Thornton & Ross.
Six bids came in to the open tender. Product quality ranked first among the criteria, ahead of overall cost and then environmental and social value.
The award was made in June 2026 at £6,532,463, about seven-tenths of the £9,489,301 estimate. No split between the suppliers was published. Supply can run to June 2029 with a 12-month extension.
Contract ends June 2028
- What
- Medicines supply
- Supplier
- 6 suppliers
- Amgen Ltd and 5 more
- Value
- £6.53m
- How it was bought
- Open procedure
- 6 bids
- Dates and next
- Oct 2026 to Jun 2028
- Being re-tendered now